Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Christoph Uherek
Observed names:
C Uherek,
C. Uherek,
Christopher Uherek,
Uherek, Christoph
Institution:
Biotest (Germany)
Observed institutions:
Boston University,
Rush University Medical Center,
University of Freiburg,
TUM Klinikum,
Biotest (Germany),
Georg Speyer Haus,
Rush University,
Technical University of Munich
show all 8
ORCID:
0000-0001-5579-6964
Observed ORCID:
0000-0001-5579-6964
OpenAlex ID:
A5061228788
CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium.
1995
·
L Piali
, P Hammel
, et al.
·
The Journal of Cell Biology
·
378
PDF
Retargeting of natural killer–cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction
2002
·
Christoph Uherek
, Torsten Tonn
, et al.
·
Blood
·
265
PDF
CD 19‐ CAR engineered NK ‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
2016
·
Annette Romanski
, Christoph Uherek
, et al.
·
Journal of Cellular and Molecular Medicine
·
227
PDF
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells
2007
·
Tina Müller
, Christoph Uherek
, et al.
·
Cancer Immunology Immunotherapy
·
221
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
2009
·
Hiroshi Ikeda
, Teru Hideshima
, et al.
·
Clinical Cancer Research
·
207
NK cells engineered to express a GD2‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin
2011
·
Ruth Esser
, Tina Müller
, et al.
·
Journal of Cellular and Molecular Medicine
·
192
PDF
In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging
2004
·
Heike E. Daldrup-Link
, Reinhardt Meier
, et al.
·
European Radiology
·
167
A Modular DNA Carrier Protein Based on the Structure of Diphtheria Toxin Mediates Target Cell-specific Gene Delivery
1998
·
Christoph Uherek
, Jesús Fominaya
, et al.
·
Journal of Biological Chemistry
·
91
PDF
DNA-carrier proteins for targeted gene delivery
2000
·
Christoph Uherek
, Winfried Wels
·
Advanced Drug Delivery Reviews
·
77
Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors
2008
·
Reinhard Meier
, Morand Piert
, et al.
·
Nuclear Medicine and Biology
·
69
A chimeric fusion protein containing transforming growth factor-α mediates gene transfer via binding to the EGF receptor
1998
·
J Fominaya
, C Uherek
, et al.
·
Gene Therapy
·
61
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
2017
·
Kurt Schönfeld
, Chantal Zuber
, et al.
·
Journal of Hematology & Oncology
·
59
BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
2011
·
Sundar Jagannath
, Asher Chanan-Khan
, et al.
·
Blood
·
44
A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway
2014
·
Bianca Helling
, Martin König
, et al.
·
Immunology and Cell Biology
·
40
PDF
Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors
2004
·
Winfried Wels
, Markus Biburger
, et al.
·
Cancer Immunology Immunotherapy
·
34
Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.
2009
·
Asher A. Chanan-Khan
, Sundar Jagannath
, et al.
·
Blood
·
25
Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models
2018
·
Kurt Schönfeld
, Peter Herbener
, et al.
·
Pharmaceutical Research
·
23
PDF
Chimeric Antigen Receptors for the Retargeting of Cytotoxic Effector Cells
2001
·
Christoph Uherek
, Bernd Groner
, et al.
·
Stem Cells and Development
·
15
BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
2010
·
Sundar Jagannath
, Asher A. Chanan-Khan
, et al.
·
Blood
·
12
Re-Targeting of an NK Cell Line (NK92) with Specificity for CD19 Efficiently Kills Human B-Precursor Leukemia Cells.
2004
·
Annette Romanski
, Christoph Uherek
, et al.
·
Blood
·
12
BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib
2010
·
Chantal Zuber
, Benjamin Daelken
, et al.
·
Blood
·
6
Genetically modified natural killer cells specifically recognizing the tumor-associated antigens ErbB2/HER2 and EpCAM
2004
·
C Uherek
, T Müller
, et al.
·
Cancer Cell International
·
6
PDF
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.
2008
·
Hiroshi Ikeda
, Teru Hideshima
, et al.
·
Blood
·
5
(1125) - Selective Activation of Naturally Occurring Regulatory T Cells (Tregs) by the Monoclonal Antibody (mAb) BT-061. Markers of Clinical Activity and Early Phase II Results in Patients with Rheumatoid Arthritis (RA)
2010
·
Anatoliy Rudnev
, Sukanya Ragavan
, et al.
·
4
The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo
2008
·
Hiroshi Ikeda
, Teru Hideshima
, et al.
·
Nature Precedings
·
3
PDF
Show more works
View as search
Works count:
39
Citation count:
2,244
H-index:
17
I10-index:
20
Year
Topic
Type
